Circular ecDNA Fuels Cancer by Amplifying Oncogene Fusion Transcripts Like PVT1-MYC
Extrachromosomal DNA has the highest oncogene fusion rate of any copy-number change. PVT1 exon 1 fusions stabilize RNA and boost MYC activity.
Summary
Extrachromosomal DNA (ecDNA) are circular, megabase-sized pieces of DNA that carry cancer genes and are linked to aggressive tumors. Analyzing genomes and transcriptomes from 1,825 matched tumor and cell line samples, researchers found that ecDNA has the highest rate of oncogene fusion of any copy-number alteration. The top hotspot was PVT1, a long noncoding RNA gene next to MYC. Fusions that keep PVT1's first exon make partner RNAs 2–3 times more stable, apparently by binding the splicing factor SRSF1 and escaping translation-coupled decay. In cell models, PVT1-MYC rescued MYC-addicted cells better than normal MYC and drove stronger MYC target gene activation. The findings explain why ecDNA tumors are so aggressive and suggest fusion transcripts could serve as ecDNA biomarkers.
Detailed Summary
Extrachromosomal DNA (ecDNA) is found in roughly 17% of tumors and is associated with oncogene amplification, rapid tumor evolution, treatment resistance and shorter survival. Gene fusions are also a cancer hallmark, but how ecDNA relates to fusion formation and function was unclear. This study asked whether ecDNA is a platform for generating and amplifying oncogenic fusion transcripts.
The team integrated amplicon classification from whole-genome sequencing with RNA fusion calls from RNA-seq for 1,825 matched samples across 83 cancer types from TCGA and the Cancer Cell Line Encyclopedia. They mapped more than 525,000 structural variants (SVs) and 23,500 RNA fusions, and validated key breakpoints with long-read DNA and RNA sequencing. Mechanistic work used the near-isogenic COLO320DM (ecDNA-borne PVT1-MYC) and COLO320HSR (chromosomal amplification) lines, along with reporter assays, actinomycin D RNA-decay measurements, ChIRP-MS, RNA immunoprecipitation, AlphaFold3 modeling, mutagenesis, MYC-depletion rescue experiments, single-cell RNA-seq and CRISPRi.
EcDNA showed the highest SV-supported fusion rate and RNA fusion frequency of any copy-number alteration. Among ecDNA-positive cancers, 55% carried ecDNA-borne fusions, and 88.5% of those fusions were SV-supported. Fusions clustered in EGFR, MYC/PVT1, MDM2 and ERBB2, with tissue-specific patterns. PVT1 was the top hotspot: 98.5% of PVT1 fusions had PVT1 at the 5′ end, and 95% retained exon 1, an 8–14-fold enrichment suggesting positive selection. Combining PVT1 fusion expression with copy-number gain raised ecDNA detection accuracy to 95%.
PVT1 exon 1 fusion increased steady-state RNA levels 2–3-fold beyond gene dosage, matching 2–3-fold slower decay. The 5′ 75 nucleotides bind SRSF1, which appears to let the transcript escape translation-coupled and nonsense-mediated decay. Deleting or mutating this site abolished stabilization. PVT1-MYC rescued MYC-depleted cells better than canonical MYC, and its expression tracked more strongly with MYC target activation in vitro and in xenografts. CRISPRi of the PVT1 promoter lowered MYC target genes.
These findings position ecDNA as a source of genome instability that produces and selects for fusions, and suggest fusion transcripts as diagnostic markers for ecDNA-positive tumors. Caveats: the mechanistic work centers on one PVT1-MYC model and reporter systems, the SRSF1 mechanism is described as potential rather than proven in all contexts, and the analysis is correlative across mostly cell line and bulk tumor data. Whether targeting this pathway is therapeutically feasible remains untested.
Key Findings
- EcDNA had the highest oncogene fusion rate of any copy-number alteration across 1,825 matched samples from 83 cancer types.
- Among ecDNA-positive cancers, 55% carried ecDNA-borne RNA fusions, and 88.5% of these were supported by structural variants.
- PVT1 is the top ecDNA fusion hotspot; 95% of its fusion transcripts keep exon 1, an 8–14-fold enrichment suggesting selection.
- PVT1 exon 1 fusion made partner RNAs 2–3-fold more stable, likely via SRSF1 binding, enabling escape from translation-coupled decay.
- PVT1-MYC rescued MYC-addicted cells better than canonical MYC and more strongly drove MYC target gene expression.
Methodology
Integrative computational analysis of matched whole-genome and RNA-seq data from 1,825 TCGA and CCLE samples, validated by long-read DNA and RNA sequencing. Mechanistic experiments in COLO320DM/HSR cells used reporter assays, RNA decay modeling, ChIRP-MS, RNA-IP, AlphaFold3 prediction, mutagenesis, MYC-depletion rescue, Flex scRNA-seq (in vitro and xenograft) and CRISPRi.
Study Limitations
Much of the evidence is correlative and comes from cell lines and bulk tumor data, with mechanistic validation concentrated on PVT1-MYC in COLO320 models and reporter constructs. The SRSF1 role is described as potential, and SRSF1 is essential and broadly acting, so causal confirmation for endogenous transcripts in other fusions is limited. No clinical outcome or treatment-response data were tested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
